{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:54:06Z","timestamp":1791154446169,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,12,31]],"date-time":"2014-12-31T00:00:00Z","timestamp":1419984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,12,31]],"date-time":"2014-12-31T00:00:00Z","timestamp":1419984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Skeletal metastases are an incurable complication afflicting the majority of patients who die from advanced breast cancer. They are most often osteolytic, characterized by net bone destruction and suppressed new bone formation. Life expectancy from first diagnosis of breast cancer bone metastases is several years, during which time skeletal-related events - including pain, fracture, hypercalcemia, and spinal cord compression - significantly degrade quality of life. The bone marrow niche can also confer hormonal and chemo-resistance. Most treatments for skeletal metastases target bone-destroying osteoclasts and are palliative. Recent results from the Breast cancer trials of Oral Everolimus-2 trial suggest that agents such as the mammalian target of rapamycin inhibitor everolimus may have efficacy against breast cancer bone metastases in part via stimulating osteoblasts as well as by inhibiting tumor growth. Selective estrogen receptor modulators similarly inhibit growth of estrogen receptor-positive breast cancers while having positive effects on the skeleton. This review discusses the future role of bone-anabolic agents for the specific treatment of osteolytic breast cancer metastases. Agents with both anti-tumor and bone-anabolic actions have been tested in the setting of multiple myeloma, a hematological malignancy that causes severe osteolytic bone loss and suppression of osteoblastic new bone formation. Stimulation of osteoblast activity inhibits multiple myeloma growth - a strategy that might decrease breast cancer burden in osteolytic bone metastases. Proteasome inhibitors (bortezomib and carfilzomib) inhibit the growth of myeloma directly and are anabolic for bone. Drugs with limited anti-tumor activity but which are anabolic for bone include intermittent parathyroid hormone and antibodies that neutralize the WNT inhibitors DKK1 and sclerostin, as well as the activin A blocker sotatercept and the osteoporosis drug strontium ranelate. Transforming growth factor-beta inhibitors have little tumor anti-proliferative activity but block breast cancer production of osteolytic factors and are also anabolic for bone. Some of these treatments are already in clinical trials. This review provides an overview of agents with bone-anabolic properties, which may have utility in the treatment of breast cancer metastatic to the skeleton.<\/jats:p>","DOI":"10.1186\/s13058-014-0484-9","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T13:41:43Z","timestamp":1419946903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Role of bone-anabolic agents in the treatment of breast cancer bone metastases"],"prefix":"10.1186","volume":"16","author":[{"given":"Attaya","family":"Suvannasankha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Chirgwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,31]]},"reference":[{"key":"484_CR1","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/bjc.1998.52","volume":"77","author":"RE Coleman","year":"1998","unstructured":"Coleman RE, Smith P, Rubens RD: Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer. 1998, 77: 336-340. 10.1038\/bjc.1998.52.","journal-title":"Br J Cancer"},{"key":"484_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.mce.2009.07.004","volume":"310","author":"S Casimiro","year":"2009","unstructured":"Casimiro S, Guise TA, Chirgwin J: The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol. 2009, 310: 71-81. 10.1016\/j.mce.2009.07.004.","journal-title":"Mol Cell Endocrinol"},{"key":"484_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.bone.2012.08.121","volume":"54","author":"CA O\u2019Brien","year":"2013","unstructured":"O\u2019Brien CA, Nakashima T, Takayanagi H: Osteocyte control of osteoclastogenesis. Bone. 2013, 54: 258-263. 10.1016\/j.bone.2012.08.121.","journal-title":"Bone"},{"key":"484_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San MJ, Dansey R: Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012, 11: 401-419. 10.1038\/nrd3705.","journal-title":"Nat Rev Drug Discov"},{"key":"484_CR5","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.ctrv.2012.02.002","volume":"38","author":"N Bundred","year":"2012","unstructured":"Bundred N: Antiresorptive therapies in oncology and their effects on cancer progression. Cancer Treat Rev. 2012, 38: 776-786. 10.1016\/j.ctrv.2012.02.002.","journal-title":"Cancer Treat Rev"},{"key":"484_CR6","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1007\/s00198-014-2808-0","volume":"12","author":"R Sapir-Koren","year":"2014","unstructured":"Sapir-Koren R, Livshits G: Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?. Osteoporos Int. 2014, 12: 2685-2700. 10.1007\/s00198-014-2808-0.","journal-title":"Osteoporos Int"},{"key":"484_CR7","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1634\/theoncologist.11-10-1121","volume":"11","author":"TA Guise","year":"2006","unstructured":"Guise TA: Bone loss and fracture risk associated with cancer therapy. Oncologist. 2006, 11: 1121-1131. 10.1634\/theoncologist.11-10-1121.","journal-title":"Oncologist"},{"key":"484_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4161\/cbt.7.1.5163","volume":"7","author":"M Akhtari","year":"2008","unstructured":"Akhtari M, Mansuri J, Newman KA, Guise TM, Seth P: Biology of breast cancer bone metastasis. Cancer Biol Ther. 2008, 7: 3-9. 10.4161\/cbt.7.1.5163.","journal-title":"Cancer Biol Ther"},{"key":"484_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/bcr2781","volume":"12","author":"YC Chen","year":"2010","unstructured":"Chen YC, Sosnoski DM, Mastro AM: Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 2010, 12: 215-10.1186\/bcr2781.","journal-title":"Breast Cancer Res"},{"key":"484_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s12307-011-0090-7","volume":"4","author":"S Vallet","year":"2011","unstructured":"Vallet S, Raje N: Bone anabolic agents for the treatment of multiple myeloma. Cancer Microenviron. 2011, 4: 339-349. 10.1007\/s12307-011-0090-7.","journal-title":"Cancer Microenviron"},{"key":"484_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.critrevonc.2013.05.015","volume":"87","author":"P Hadji","year":"2013","unstructured":"Hadji P, Coleman R, Gnant M: Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Crit Rev Oncol Hematol. 2013, 87: 101-111. 10.1016\/j.critrevonc.2013.05.015.","journal-title":"Crit Rev Oncol Hematol"},{"key":"484_CR12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012, 366: 520-529. 10.1056\/NEJMoa1109653.","journal-title":"N Engl J Med"},{"key":"484_CR13","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.ejca.2009.09.026","volume":"45","author":"P Hadji","year":"2009","unstructured":"Hadji P, Ziller M, Maskow C, Albert U, Kalder M: The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. Eur J Cancer. 2009, 45: 3205-3212. 10.1016\/j.ejca.2009.09.026.","journal-title":"Eur J Cancer"},{"key":"484_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000321426","volume":"5","author":"P Hadji","year":"2010","unstructured":"Hadji P: Guidelines for osteoprotection in breast cancer patients on an aromatase inhibitor. Breast Care (Basel). 2010, 5: 290-296. 10.1159\/000321426.","journal-title":"Breast Care (Basel)"},{"key":"484_CR15","doi-asserted-by":"publisher","first-page":"15541","DOI":"10.1073\/pnas.0805354105","volume":"105","author":"A Yano","year":"2008","unstructured":"Yano A, Tsutsumi S, Soga S, Lee MJ, Trepel J, Osada H, Neckers L: Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci USA. 2008, 105: 15541-15546. 10.1073\/pnas.0805354105.","journal-title":"Proc Natl Acad Sci USA"},{"key":"484_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/187152012800228797","volume":"12","author":"JM Chirgwin","year":"2012","unstructured":"Chirgwin JM: The stem cell niche as a pharmaceutical target for prevention of skeletal metastases. Anticancer Agents Med Chem. 2012, 12: 187-193. 10.2174\/187152012800228797.","journal-title":"Anticancer Agents Med Chem"},{"key":"484_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2174\/1566524023362401","volume":"2","author":"G Motyckova","year":"2002","unstructured":"Motyckova G, Fisher DE: Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. Curr Mol Med. 2002, 2: 407-421. 10.2174\/1566524023362401.","journal-title":"Curr Mol Med"},{"key":"484_CR18","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1172\/JCI36898E1","volume":"118","author":"S Grant","year":"2008","unstructured":"Grant S: Co-targeting survival signaling pathways in cancer. J Clin Invest. 2008, 118: 3003-3006. 10.1172\/JCI36898E1.","journal-title":"J Clin Invest"},{"key":"484_CR19","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/sj.cdd.4401285","volume":"10","author":"H Glantschnig","year":"2003","unstructured":"Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA: M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR\/S6 kinase. Cell Death Differ. 2003, 10: 1165-1177. 10.1038\/sj.cdd.4401285.","journal-title":"Cell Death Differ"},{"key":"484_CR20","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.bone.2004.07.013","volume":"35","author":"M Kneissel","year":"2004","unstructured":"Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, O\u2019Reilly T, Lane H, Susa M: Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone. 2004, 35: 1144-1156. 10.1016\/j.bone.2004.07.013.","journal-title":"Bone"},{"key":"484_CR21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","volume":"110","author":"N Giuliani","year":"2007","unstructured":"Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, Mancini C, Martella E, Ferrari L, Tabilio A, Rizzoli V: The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007, 110: 334-338. 10.1182\/blood-2006-11-059188.","journal-title":"Blood"},{"key":"484_CR22","first-page":"491","volume":"118","author":"S Mukherjee","year":"2008","unstructured":"Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, Jones DC, Vallet S, Bouxsein ML, Pozzi S, Chhetri S, Seo YD, Aronson JP, Patel C, Fulciniti M, Purton LE, Glimcher LH, Lian JB, Stein G, Anderson KC, Scadden DT: Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest. 2008, 118: 491-504.","journal-title":"J Clin Invest"},{"key":"484_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/leu.2012.183","volume":"27","author":"MA Hurchla","year":"2013","unstructured":"Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN: The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia. 2013, 27: 430-440. 10.1038\/leu.2012.183.","journal-title":"Leukemia"},{"key":"484_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","volume":"77","author":"U Heider","year":"2006","unstructured":"Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz CO, Fleissner C, Hecht M, Sezer O: Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol. 2006, 77: 233-238. 10.1111\/j.1600-0609.2006.00692.x.","journal-title":"Eur J Haematol"},{"key":"484_CR25","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1038\/leu.2008.235","volume":"22","author":"E Terpos","year":"2008","unstructured":"Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA: The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed\/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia. 2008, 22: 2247-2256. 10.1038\/leu.2008.235.","journal-title":"Leukemia"},{"key":"484_CR26","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","volume":"135","author":"E Terpos","year":"2006","unstructured":"Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI: Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol. 2006, 135: 688-692. 10.1111\/j.1365-2141.2006.06356.x.","journal-title":"Br J Haematol"},{"key":"484_CR27","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1158\/1078-0432.CCR-09-3293","volume":"16","author":"MD Jones","year":"2010","unstructured":"Jones MD, Liu JC, Barthel TK, Hussain S, Lovria E, Cheng D, Schoonmaker JA, Mulay S, Ayers DC, Bouxsein ML, Stein GS, Mukherjee S, Lian JB: A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res. 2010, 16: 4978-4989. 10.1158\/1078-0432.CCR-09-3293.","journal-title":"Clin Cancer Res"},{"key":"484_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3816\/CBC.2010.n.061","volume":"10","author":"WJ Irvin Jr","year":"2010","unstructured":"Irvin WJ, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, Stijleman IJ, Perou C, Ivanova A, Dees EC: Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clin Breast Cancer. 2010, 10: 465-470. 10.3816\/CBC.2010.n.061.","journal-title":"Clin Breast Cancer"},{"key":"484_CR29","first-page":"192","volume":"91","author":"S Yaccoby","year":"2006","unstructured":"Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J: Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006, 91: 192-199.","journal-title":"Haematologica"},{"key":"484_CR30","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.yexcr.2009.04.026","volume":"315","author":"R Krawetz","year":"2009","unstructured":"Krawetz R, Wu YE, Rancourt DE, Matyas J: Osteoblasts suppress high bone turnover caused by osteolytic breast cancer in-vitro. Exp Cell Res. 2009, 315: 2333-2342. 10.1016\/j.yexcr.2009.04.026.","journal-title":"Exp Cell Res"},{"key":"484_CR31","doi-asserted-by":"publisher","first-page":"e15233","DOI":"10.1371\/journal.pone.0015233","volume":"5","author":"A Pennisi","year":"2010","unstructured":"Pennisi A, Ling W, Li X, Khan S, Wang Y, Barlogie B, Shaughnessy JD, Yaccoby S: Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS One. 2010, 5: e15233-10.1371\/journal.pone.0015233.","journal-title":"PLoS One"},{"key":"484_CR32","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/leu.2011.381","volume":"26","author":"N Giuliani","year":"2012","unstructured":"Giuliani N, Ferretti M, Bolzoni M, Storti P, Lazzaretti M, Dalla Palma B, Bonomini S, Martella E, Agnelli L, Neri A, Ceccarelli F, Palumbo C: Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia. 2012, 26: 1391-1401. 10.1038\/leu.2011.381.","journal-title":"Leukemia"},{"key":"484_CR33","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/jnci\/djr242","volume":"103","author":"E Amir","year":"2011","unstructured":"Amir E, Seruga B, Niraula S, Carlsson L, Ocana A: Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011, 103: 1299-1309. 10.1093\/jnci\/djr242.","journal-title":"J Natl Cancer Inst"},{"key":"484_CR34","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.bone.2007.08.026","volume":"41","author":"P Haentjens","year":"2007","unstructured":"Haentjens P, Autier P, Barette M, Venken K, Vanderschueren D, Boonen S: Survival and functional outcome according to hip fracture type: a one-year prospective cohort study in elderly women with an intertrochanteric or femoral neck fracture. Bone. 2007, 41: 958-964. 10.1016\/j.bone.2007.08.026.","journal-title":"Bone"},{"key":"484_CR35","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s00774-013-0494-1","volume":"31","author":"JJ Stepan","year":"2013","unstructured":"Stepan JJ: Strontium ranelate: in search for the mechanism of action. J Bone Miner Metab. 2013, 31: 606-612. 10.1007\/s00774-013-0494-1.","journal-title":"J Bone Miner Metab"},{"key":"484_CR36","first-page":"703","volume":"125","author":"SC Skoryna","year":"1981","unstructured":"Skoryna SC: Effects of oral supplementation with stable strontium. Can Med Assoc J. 1981, 125: 703-712.","journal-title":"Can Med Assoc J"},{"key":"484_CR37","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1158\/1078-0432.CCR-13-0839","volume":"20","author":"J Dai","year":"2014","unstructured":"Dai J, Zhang H, Karatsinides A, Keller JM, Kozloff KM, Aftab DT, Schimmoller F, Keller ET: Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res. 2014, 20: 617-630. 10.1158\/1078-0432.CCR-13-0839.","journal-title":"Clin Cancer Res"},{"key":"484_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.drudis.2013.07.021","volume":"19","author":"HK Ho","year":"2014","unstructured":"Ho HK, Yeo AH, Kang TS, Chua BT: Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations. Drug Discov Today. 2014, 19: 51-62. 10.1016\/j.drudis.2013.07.021.","journal-title":"Drug Discov Today"},{"key":"484_CR39","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/jbmr.1810","volume":"28","author":"S W\u00f6hrle","year":"2013","unstructured":"W\u00f6hrle S, Henninger C, Bonny O, Thuery A, Beluch N, Hynes NE, Guagnano V, Sellers WR, Hofmann F, Kneissel M, Graus Porta D: Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013, 28: 899-911. 10.1002\/jbmr.1810.","journal-title":"J Bone Miner Res"},{"key":"484_CR40","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nrc3500","volume":"13","author":"LM Wakefield","year":"2013","unstructured":"Wakefield LM, Hill CS: Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat Rev Cancer. 2013, 13: 328-341. 10.1038\/nrc3500.","journal-title":"Nat Rev Cancer"},{"key":"484_CR41","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/jcp.22272","volume":"225","author":"G Leto","year":"2010","unstructured":"Leto G: Activin A and bone metastasis. J Cell Physiol. 2010, 225: 302-309. 10.1002\/jcp.22272.","journal-title":"J Cell Physiol"},{"key":"484_CR42","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1073\/pnas.0911929107","volume":"107","author":"S Vallet","year":"2010","unstructured":"Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, Santo L, Cirstea D, Patel K, Sohani AR, Guimaraes A, Xie W, Chauhan D, Schoonmaker JA, Attar E, Churchill M, Weller E, Munshi N, Seehra JS, Weissleder R, Anderson KC, Scadden DT, Raje N: Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA. 2010, 107: 5124-5129. 10.1073\/pnas.0911929107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"484_CR43","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1093\/annonc\/mds068","volume":"23","author":"E Terpos","year":"2012","unstructured":"Terpos E, Kastritis E, Christoulas D, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N, Papatheodorou A, Dimopoulos MA: Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol. 2012, 23: 2681-2686. 10.1093\/annonc\/mds068.","journal-title":"Ann Oncol"},{"key":"484_CR44","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.bone.2010.01.370","volume":"46","author":"S Lotinun","year":"2010","unstructured":"Lotinun S, Pearsall RS, Davies MV, Marvell TH, Monnell TE, Ucran J, Fajardo RJ, Kumar R, Underwood KW, Seehra J, Bouxsein ML, Baron R: A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone. 2010, 46: 1082-1088. 10.1016\/j.bone.2010.01.370.","journal-title":"Bone"},{"key":"484_CR45","doi-asserted-by":"publisher","first-page":"P5-20-03","DOI":"10.1158\/0008-5472.SABCS12-P5-20-03","volume":"72","author":"M Auerbach","year":"2012","unstructured":"Auerbach M, Osborne CRC, Klesczewski K, Laadem A, Bianca R: A phase 2, double-blind, randomized, placebo-controlled, dose-finding study of sotatercept for the treatment of patients with chemotherapy-induced anemia and metastatic breast cancer. Cancer Res. 2012, 72: P5-20-03-10.1158\/0008-5472.SABCS12-P5-20-03.","journal-title":"Cancer Res"},{"key":"484_CR46","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/jbmr.142","volume":"25","author":"AD Chantry","year":"2010","unstructured":"Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud\u2019huin M, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML, Key ML, Seehra J, Arnett TR, Vanderkerken K, Croucher P: Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res. 2010, 25: 2633-2646. 10.1002\/jbmr.142.","journal-title":"J Bone Miner Res"},{"key":"484_CR47","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/bonekey.2012.96","volume":"1","author":"JT Buijs","year":"2012","unstructured":"Buijs JT, Stayrook KR, Guise TA: The role of TGF-\u03b2 in bone metastasis: novel therapeutic perspectives. Bonekey Rep. 2012, 1: 96-10.1038\/bonekey.2012.96.","journal-title":"Bonekey Rep"},{"key":"484_CR48","doi-asserted-by":"publisher","first-page":"e5275","DOI":"10.1371\/journal.pone.0005275","volume":"4","author":"KS Mohammad","year":"2009","unstructured":"Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, Davis H, Niewolna M, Peng XH, Nguyen DH, Ionova-Martin SS, Bracey JW, Hogue WR, Wong DH, Ritchie RO, Suva LJ, Derynck R, Guise TA, Alliston T: Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One. 2009, 4: e5275-10.1371\/journal.pone.0005275.","journal-title":"PLoS One"},{"key":"484_CR49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ccr.2010.12.022","volume":"19","author":"N Sethi","year":"2011","unstructured":"Sethi N, Dai X, Winter CG, Kang Y: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 2011, 19: 192-205. 10.1016\/j.ccr.2010.12.022.","journal-title":"Cancer Cell"},{"key":"484_CR50","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1210\/er.2011-1060","volume":"33","author":"HZ Ke","year":"2012","unstructured":"Ke HZ, Richards WG, Li X, Ominsky MS: Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012, 33: 747-783. 10.1210\/er.2011-1060.","journal-title":"Endocr Rev"},{"key":"484_CR51","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3109\/10428194.2013.820288","volume":"55","author":"IB Kristensen","year":"2014","unstructured":"Kristensen IB, Christensen JH, Lyng MB, Moller MB, Pedersen L, Rasmussen LM, Ditzel HJ, Abildgaard N: Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease. Leuk Lymphoma. 2014, 55: 911-919. 10.3109\/10428194.2013.820288.","journal-title":"Leuk Lymphoma"},{"key":"484_CR52","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/sj.bjc.6603959","volume":"97","author":"N Voorzanger-Rousselot","year":"2007","unstructured":"Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clezardin P, Garnero P: Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer. 2007, 97: 964-970.","journal-title":"Br J Cancer"},{"key":"484_CR53","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/bcr3048","volume":"13","author":"D Mendoza-Villanueva","year":"2011","unstructured":"Mendoza-Villanueva D, Zeef L, Shore P: Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2\/CBF\u03b2-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res. 2011, 13: R106-10.1186\/bcr3048.","journal-title":"Breast Cancer Res"},{"key":"484_CR54","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/bjh.13056","volume":"167","author":"SP Iyer","year":"2014","unstructured":"Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC: A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol. 2014, 167: 366-375. 10.1111\/bjh.13056.","journal-title":"Br J Haematol"},{"key":"484_CR55","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG: Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014, 370: 412-420. 10.1056\/NEJMoa1305224.","journal-title":"N Engl J Med"},{"key":"484_CR56","doi-asserted-by":"publisher","first-page":"21346","DOI":"10.1074\/jbc.M112.355834","volume":"287","author":"M Tarragona","year":"2012","unstructured":"Tarragona M, Pavlovic M, Arnal-Estape A, Urosevic J, Morales M, Guiu M, Planet E, Gonzalez-Suarez E, Gomis RR: Identification of NOG as a specific breast cancer bone metastasis-supporting gene. J Biol Chem. 2012, 287: 21346-21355. 10.1074\/jbc.M112.355834.","journal-title":"J Biol Chem"},{"key":"484_CR57","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4161\/cam.20888","volume":"6","author":"K Matsuo","year":"2012","unstructured":"Matsuo K, Otaki N: Bone cell interactions through Eph\/ephrin: bone modeling, remodeling and associated diseases. Cell Adh Migr. 2012, 6: 148-156. 10.4161\/cam.20888.","journal-title":"Cell Adh Migr"},{"key":"484_CR58","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1182\/blood-2009-01-201954","volume":"114","author":"A Pennisi","year":"2009","unstructured":"Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD, Barlogie B, Yaccoby S: The ephrinB2\/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood. 2009, 114: 1803-1812. 10.1182\/blood-2009-01-201954.","journal-title":"Blood"},{"key":"484_CR59","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/bonekey.2012.183","volume":"1","author":"T Negishi-Koga","year":"2012","unstructured":"Negishi-Koga T, Takayanagi H: Bone cell communication factors and Semaphorins. Bonekey Rep. 2012, 1: 183-10.1038\/bonekey.2012.183.","journal-title":"Bonekey Rep"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-014-0484-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-014-0484-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-014-0484-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-014-0484-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:06:12Z","timestamp":1728921972000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-014-0484-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,31]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,12]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1186\/s13058-014-0484-9","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,31]]},"assertion":[{"value":"31 December 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"484"}}